Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeCLINICAL TRIALS, STUDIES, DATARenalGuard Therapy Clinical Trial Results Published in the European Journal of Cardio-Thoracic...

RenalGuard Therapy Clinical Trial Results Published in the European Journal of Cardio-Thoracic Surgery

December 7, 2020

RenalGuard Therapy better protects at-risk patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from Acute Kidney Injury (AKI) according to the KIDNEY clinical trial reports RenalGuard Solutions, a pioneering medical device company focused on protecting patients from AK.

Results of the 220 patient, randomized trial comparing automated diuresis technology to standard hydration were published in the European Journal of Cardio-Thoracic Surgery. The 220-patient study was conducted by investigators at the Heart and Lung Centre, New Cross Hospital in Wolverhampton, United Kingdom.

Millions of elective cardiac surgeries are performed each year worldwide, and AKI is the most common major surgical complication, reported in up to 30% of cases. In emergent cases, AKI rates can be twice as high, ranging from 50-70%. AKI complicates patient recovery, adds significant recovery time and is one of the strongest predictors of in-hospital and long-term mortality after surgery.

In the KIDNEY trial, patients at-risk for AKI were randomized into either a RenalGuard Therapy treatment group or a control group managed with standard-of-care hydration. Risk factors for AKI included a history of diabetes and or anemia; estimated Glomerular Filtration Rate (eGFR) < 60 ml/min/1.72m2; anticipated cardiac surgery time >120 minutes and Log EuroScore > 5. AKI was defined as a rise in serum creatinine greater than 50% in the days post-procedure.

The RenalGuard group’s post-operative AKI rates were significantly lower than the control group’s, 10% vs 20.9%. As well, the mean volumes of urine produced during surgery (2337 + 896 ml vs 766 + 557 ml) and within 24 hours post-op in ICU (3297 + 1298 ml vs 2053 + 802 ml) were significantly higher in the RenalGuard group. Median ICU stays were similar for the two groups.

The investigators led by Dr. Heyman Luckraz concluded that: “In patients at risk for AKI who had cardiac surgery with CPB, the RG system significantly reduced the incidence of AKI and can be used safely and reproducibly.”

RenalGuard Therapy entails use of RenalGuard’s automated fluid management system with a physician-prescribed loop diuretic to induce high urine output rates, which protect against AKI. Used with more than 30,000 patients, the automated fluid management system is designed to measure urine output and replace it in real-time with an equal volume of sterile saline.

“We are very gratified by the results of this comprehensive study of RenalGuard in the cardiac surgery setting, which show this technology’s promise in this area as a means to protect a very high-risk population from cardiac surgery-associated AKI,” said RenalGuard Solutions President and Chief Executive Officer, Jim Dillon. “We look forward to further exploring the use of RenalGuard to reduce the incidence of AKI in this patient population.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy